FEMASYS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
FEMASYS INC. - More news...
FEMASYS INC. - More news...
- Femasys Inc. Obtains Medical Device Establishment License from Health Canada
- Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update
- Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc
- Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control
- Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women
- Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences
- Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023
- Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada
- Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023
- Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting
- Femasys’ FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada
- Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology
- Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada
- Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update
- Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023
- Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device
- Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons
- Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design
- Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference
- Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update
- Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress
- Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs
- Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control
- Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team
- Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update
- Femasys To Participate in Upcoming BTIG Biotechnology Conference
- Femasys To Host Key Opinion Leader Event on FemBloc, a First-of-its-Kind Medical Solution for Permanent Birth Control and an Important Option for Women Post Overturn of Roe v. Wade
- Femasys to Participate in the Women’s Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, July 13th at 11 a.m. ET